Weekly paclitaxel—still preferred first-line taxane for mBC
Authors:
- 11 August 2015
- journal article
- research article
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 12 (9) , 508-509
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance)Journal of Clinical Oncology, 2015
- Taxane-containing regimens for metastatic breast cancerCochrane Database of Systematic Reviews, 2015
- Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2014
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)Annals of Oncology, 2014
- Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathyBreast Cancer Research and Treatment, 2013
- A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancerBreast Cancer Research and Treatment, 2013
- Phase II Trial of Nab-Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall SurvivalClinical Breast Cancer, 2012
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Preclinical Pharmacology of the Taxanes: Implications of the DifferencesThe Oncologist, 2004
- Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failureBritish Journal of Cancer, 2002